Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?

Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 65th American Society of Hematology (ASH).

The data in the ASH abstract published today is from a June 2, 2023 data cut and will include new data with a median follow-up of 26.5 months.

As detailed in the abstract, 38 patients were evaluable for efficacy and safety analysis, based on a median follow-up of 22 months following treatment.

Related: Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential.

These evaluable patients comprised the dose escalation cohorts for the first dose level (100 (+/- 20) million CAR+ T cells, n=6) and the second dose level (300 (+/- 20) million CAR+ T cells, n=6), and a dose expansion cohort at 100 (+/- 20) million CAR+ T cells (n=26).

Of the 38 evaluable patients with a median follow-up of 22 months, a 100% overall response rate (ORR) was achieved in all patients.

29 of 38 evaluable patients achieved a complete response (CR) or a stringent complete response (sCR) (> CR rate, 76%)

35 patients achieved a very good partial response or higher (>VGPR rate, 92%)

The median duration of response, progression-free survival (PFS), and overall survival were not reached at the time of the June 2, 2023 data cut because 25 of 38 (66%) evaluable patients had ongoing responses.

The Kaplan-Meier method estimated PFS rates for 6, 12, and 18 months were 92%, 74%, and 67% respectively.

Durable responses were also observed in patients with high-risk features and high-risk cytogenetics.

Price Action: ACLX shares are up 17.30% at $40.35 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!